BACKGROUND: Acne is commonplace in adolescents and can be difficult to manage. Providing an effective and well-tolerated treatment may lead to improved adherence, increased patient satisfaction, and improved clinical outcomes. METHODS: A post hoc analysis of efficacy and cutaneous tolerability in 289 adolescents (age range, 12 to <18 years) with moderate-to-severe acne who had been enrolled in a multicenter study and were randomized to receive either clindamycin phosphate 1.2%/benzoyl peroxide 3.75% gel or vehicle once daily for 12 weeks. RESULTS: Significantly superior reductions in lesion counts were observed in the clindamycin phosphate 1.2%/benzoyl peroxide 3.75% gel group compared to vehicle from Week 4, with mean percent reductions in inflammatory and noninflammatory lesions from baseline of 59.9 percent and 50.5 percent, respectively (both P<0.001 versus vehicle). One-third of patients treated with clindamycin phosphate 1.2%/benzoyl peroxide 3.75% gel achieved ≥2-grade improvement from baseline in their Evaluator's Global Severity Score (compared to 8.5% with vehicle, P<0.001) and 35 percent of patients reported clear or almost clear skin at Week 12 (compared to 12.8% with vehicle, P<0.001). Cutaneous tolerability was excellent with all mean scores ≤0.2 at Week 12 (where 1=mild). CONCLUSIONS:Clindamycin phosphate 1.2%/benzoyl peroxide 3.75% gel is an effective, safe, well-tolerated treatment for adolescents with moderate-to-severe acne.
RCT Entities:
BACKGROUND: Acne is commonplace in adolescents and can be difficult to manage. Providing an effective and well-tolerated treatment may lead to improved adherence, increased patient satisfaction, and improved clinical outcomes. METHODS: A post hoc analysis of efficacy and cutaneous tolerability in 289 adolescents (age range, 12 to <18 years) with moderate-to-severe acne who had been enrolled in a multicenter study and were randomized to receive either clindamycin phosphate 1.2%/benzoyl peroxide 3.75% gel or vehicle once daily for 12 weeks. RESULTS: Significantly superior reductions in lesion counts were observed in the clindamycin phosphate 1.2%/benzoyl peroxide 3.75% gel group compared to vehicle from Week 4, with mean percent reductions in inflammatory and noninflammatory lesions from baseline of 59.9 percent and 50.5 percent, respectively (both P<0.001 versus vehicle). One-third of patients treated with clindamycin phosphate 1.2%/benzoyl peroxide 3.75% gel achieved ≥2-grade improvement from baseline in their Evaluator's Global Severity Score (compared to 8.5% with vehicle, P<0.001) and 35 percent of patients reported clear or almost clear skin at Week 12 (compared to 12.8% with vehicle, P<0.001). Cutaneous tolerability was excellent with all mean scores ≤0.2 at Week 12 (where 1=mild). CONCLUSIONS:Clindamycin phosphate 1.2%/benzoyl peroxide 3.75% gel is an effective, safe, well-tolerated treatment for adolescents with moderate-to-severe acne.
Authors: Diane Thiboutot; Harald Gollnick; Vincenzo Bettoli; Brigitte Dréno; Sewon Kang; James J Leyden; Alan R Shalita; Vicente Torres Lozada; Diane Berson; Andrew Finlay; Chee Leok Goh; María Isabel Herane; Ana Kaminsky; Raj Kubba; Alison Layton; Yoshiki Miyachi; Montserrat Perez; Jaime Piquero Martin; Marcia Ramos-E-Silva; Jo Ann See; Neil Shear; John Wolf Journal: J Am Acad Dermatol Date: 2009-05 Impact factor: 11.527
Authors: Diane Thiboutot; Andrea Zaenglein; Jonathan Weiss; Guy Webster; Barry Calvarese; Diana Chen Journal: J Am Acad Dermatol Date: 2008-09-20 Impact factor: 11.527
Authors: Brigitte Dréno; Diane Thiboutot; Harald Gollnick; Andrew Y Finlay; Alison Layton; James J Leyden; Eric Leutenegger; Montserrat Perez Journal: Int J Dermatol Date: 2010-04 Impact factor: 2.736